Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
60 participants
INTERVENTIONAL
2016-06-30
2021-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
hypofraction
70 Gy in 28 fractions over 5.6 weeks
hypofraction
70 Gy in 28 fractions over 5.6 weeks
convention
80Gy in 40 fractions over 8 weeks
convention
80Gy in 40 fractions over 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
hypofraction
70 Gy in 28 fractions over 5.6 weeks
convention
80Gy in 40 fractions over 8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed prostate adenocarcinoma
* Clinical stage T1-3N0M0 according to the AJCC 6th edition
* Gleason score must be \>5
* KPS \>70
* No radical surgery or cryosurgery for prostate cancer
Exclusion Criteria
* Evidence of distant metastases
* Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
* Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
* Previous or concurrent cytotoxic chemotherapy for prostate cancer
50 Years
79 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gaofing Li
director of radiotherapy department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gaofeng Li, director
Role: PRINCIPAL_INVESTIGATOR
Beijing Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Gaofeng Li
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BeijingH-01-RT
Identifier Type: -
Identifier Source: org_study_id